Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension.

RATIONALE Limited information is available on racial/ethnic differences in pulmonary arterial hypertension (PAH). OBJECTIVES Determine effects of race/ethnicity and ancestry on mortality and disease outcomes in diverse patients with PAH. METHODS Group 1 PAH patients were included from two national registries with genome-wide data and two local cohorts and further incorporated in a global meta-analysis. Hazard ratios (HRs) were calculated for transplant-free all-cause mortality in Hispanics with Non-Hispanic whites (NHWs) as the reference group. Odds ratios (ORs) for inpatient-specific mortality in PAH patients were also calculated for race/ethnic groups from an additional National Inpatient Sample (NIS) dataset, not included in the meta-analysis. MEASUREMENTS AND MAIN RESULTS After covariate adjustment, self-reported Hispanics (n=290) exhibited significantly reduced mortality versus NHWs (n=1970) after global meta-analysis (HR 0.60[0.41-0.87], p=0.008). Although not significant, increasing Native American genetic ancestry appeared to account for part of the observed mortality benefit (HR 0.48[0.23-1.01], p=0.053) in the two national registries. Finally, in the NIS, an inpatient mortality benefit was also observed for Hispanics (n=1524) versus NHWs (n=8829; OR 0.65[0.50-0.84], p=0.001). An inpatient mortality benefit was observed for Native Americans (n=185; OR 0.38[0.15-0.93], p=0.034). CONCLUSIONS This study demonstrates a reproducible survival benefit for Hispanic Group 1 PAH patients in multiple clinical settings. Our results implicate contributions of genetic ancestry to differential survival in PAH.

[1]  R. Benza,et al.  Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. , 2019, Chest.

[2]  B. Dean,et al.  Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms , 2019, Annals of the American Thoracic Society.

[3]  M. Humbert,et al.  Prostacyclin for pulmonary arterial hypertension. , 2019, The Cochrane database of systematic reviews.

[4]  Lisa J. Martin,et al.  Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis , 2018, bioRxiv.

[5]  Andrew B. Conley,et al.  Genetic ancestry, admixture and health determinants in Latin America , 2018, BMC Genomics.

[6]  Henning Gall,et al.  Identification of rare sequence variation underlying heritable pulmonary arterial hypertension , 2018, Nature Communications.

[7]  V. Rowe,et al.  Controversies and evidence for cardiovascular disease in the diverse Hispanic population. , 2017, Journal of vascular surgery.

[8]  Sarah K. Medrek,et al.  Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine , 2017, Chest.

[9]  J. Paulus,et al.  Racial and ethnic differences in pulmonary arterial hypertension , 2017, Pulmonary circulation.

[10]  M. Humbert,et al.  Epidemiology and treatment of pulmonary arterial hypertension , 2017, Nature Reviews Cardiology.

[11]  O. Sitbon,et al.  Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience , 2017, European Respiratory Review.

[12]  H. Shimoura,et al.  Right ventricular relative wall thickness as a predictor of outcomes and of right ventricular reverse remodeling for patients with pulmonary hypertension , 2017, The International Journal of Cardiovascular Imaging.

[13]  S. Archer,et al.  Trends and Outcomes of Pulmonary Arterial Hypertension-Related Hospitalizations in the United States: Analysis of the Nationwide Inpatient Sample Database From 2001 Through 2012. , 2016, JAMA cardiology.

[14]  Stephen Kaptoge,et al.  BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis , 2016, The Lancet. Respiratory medicine.

[15]  A. Torbicki,et al.  Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.

[16]  Carl D. Langefeld,et al.  Genomic Insights into the Ancestry and Demographic History of South America , 2015, PLoS genetics.

[17]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[18]  C. Sabatti,et al.  Characterizing Race/Ethnicity and Genetic Ancestry for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort , 2015, Genetics.

[19]  R. Safford,et al.  Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. , 2015, Chest.

[20]  M. Hoeper,et al.  The changing landscape of pulmonary arterial hypertension and implications for patient care , 2014, European Respiratory Review.

[21]  F. Lopez‐Jimenez,et al.  The Hispanic paradox in cardiovascular disease and total mortality. , 2014, Progress in cardiovascular diseases.

[22]  E. Bergot,et al.  Increase of pulmonary artery wedge pressure above 15 mm Hg in patients with pre-capillary pulmonary hypertension , 2014 .

[23]  D. Balding,et al.  Admixture in Latin America: Geographic Structure, Phenotypic Diversity and Self-Perception of Ancestry Based on 7,342 Individuals , 2014, PLoS genetics.

[24]  R. Damico,et al.  Severity of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension in African Americans , 2014, Medicine.

[25]  Mary G. George,et al.  Pulmonary Hypertension Surveillance , 2014, Chest.

[26]  W. Chung,et al.  Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension , 2013, Nature Genetics.

[27]  S. Archer,et al.  Evolving epidemiology of pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[28]  Christopher R. Gignoux,et al.  Development of a Panel of Genome-Wide Ancestry Informative Markers to Study Admixture Throughout the Americas , 2012, PLoS genetics.

[29]  A. Torbicki,et al.  Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. , 2012, Pulmonary pharmacology & therapeutics.

[30]  H. Palevsky,et al.  Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. , 2012, Chest.

[31]  R. Kronmal,et al.  Sex and Race Differences in Right Ventricular Structure and Function: The Multi-Ethnic Study of Atherosclerosis–Right Ventricle Study , 2011, Circulation.

[32]  Sindhu R. Johnson,et al.  Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. , 2010, Respiratory medicine.

[33]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[34]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[35]  S. Ghio,et al.  Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. , 2010, International journal of cardiology.

[36]  T. Fleming,et al.  Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. , 2008, Chest.

[37]  M. Humbert,et al.  Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. , 2008, American journal of respiratory and critical care medicine.

[38]  J. Bronzwaer,et al.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. , 2007, European heart journal.

[39]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[40]  J. Kere,et al.  BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension , 2005, Human mutation.

[41]  J. Loyd,et al.  Primary pulmonary hypertension , 2003, The Lancet.

[42]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[43]  G. Koch,et al.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[44]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[45]  D. Lilienfeld,et al.  Mortality from primary pulmonary hypertension in the United States, 1979-1996. , 2000, Chest.

[46]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.